Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285198681> ?p ?o ?g. }
- W4285198681 endingPage "5050" @default.
- W4285198681 startingPage "5034" @default.
- W4285198681 abstract "Background: Given the importance of microvascular injury in infarct formation and expansion, development of therapeutic strategies for microvascular protection against myocardial ischemia/reperfusion injury (IRI) is of great interest. Here, we explored the molecular mechanisms underlying the protective effects of the SGLT2 inhibitor dapagliflozin (DAPA) against cardiac microvascular dysfunction mediated by IRI. Methods: DAPA effects were evaluated both in vivo, in mice subjected to IRI, and in vitro, in human coronary artery endothelial cells (HCAECs) exposed to hypoxia/reoxygenation (H/R). DAPA pretreatment attenuated luminal stenosis, endothelial swelling, and inflammation in cardiac microvessels of IRI-treated mice. Results: In H/R-challenged HCAECs, DAPA treatment improved endothelial barrier function, endothelial nitric oxide synthase (eNOS) activity, and angiogenic capacity, and inhibited H/R-induced apoptosis by preventing cofilin-dependent F-actin depolymerization and cytoskeletal degradation. Inhibition of H/R-induced xanthine oxidase (XO) activation and upregulation, sarco(endo)plasmic reticulum calcium-ATPase 2 (SERCA2) oxidation and inactivation, and cytoplasmic calcium overload was further observed in DAPA-treated HCAECs. DAPA also suppressed calcium/Calmodulin (CaM)-dependent kinase II (CaMKII) activation and cofilin phosphorylation, and preserved cytoskeleton integrity and endothelial cell viability following H/R. Importantly, the beneficial effects of DAPA on cardiac microvascular integrity and endothelial cell survival were largely prevented in IRI-treated SERCA2-knockout mice. Conclusions: These results indicate that DAPA effectively reduces cardiac microvascular damage and endothelial dysfunction during IRI through inhibition of the XO-SERCA2-CaMKII-cofilin pathway." @default.
- W4285198681 created "2022-07-14" @default.
- W4285198681 creator A5000521986 @default.
- W4285198681 creator A5008721029 @default.
- W4285198681 creator A5018072765 @default.
- W4285198681 creator A5022684433 @default.
- W4285198681 creator A5026641678 @default.
- W4285198681 creator A5041492302 @default.
- W4285198681 creator A5047312522 @default.
- W4285198681 creator A5058382693 @default.
- W4285198681 date "2022-01-01" @default.
- W4285198681 modified "2023-10-10" @default.
- W4285198681 title "SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways" @default.
- W4285198681 cites W1484094963 @default.
- W4285198681 cites W1518531052 @default.
- W4285198681 cites W1966984402 @default.
- W4285198681 cites W1970534551 @default.
- W4285198681 cites W1971656523 @default.
- W4285198681 cites W1981585250 @default.
- W4285198681 cites W2003648386 @default.
- W4285198681 cites W2006496714 @default.
- W4285198681 cites W2010217891 @default.
- W4285198681 cites W2019650322 @default.
- W4285198681 cites W2020081859 @default.
- W4285198681 cites W2056180067 @default.
- W4285198681 cites W2058839055 @default.
- W4285198681 cites W2089925679 @default.
- W4285198681 cites W2102083961 @default.
- W4285198681 cites W2119416582 @default.
- W4285198681 cites W2151345870 @default.
- W4285198681 cites W2160458790 @default.
- W4285198681 cites W2169639006 @default.
- W4285198681 cites W2181241483 @default.
- W4285198681 cites W2332664660 @default.
- W4285198681 cites W2440136372 @default.
- W4285198681 cites W2516573111 @default.
- W4285198681 cites W2596407801 @default.
- W4285198681 cites W2725230559 @default.
- W4285198681 cites W2747826704 @default.
- W4285198681 cites W2777514005 @default.
- W4285198681 cites W2790125420 @default.
- W4285198681 cites W2790216199 @default.
- W4285198681 cites W2791379001 @default.
- W4285198681 cites W2794268420 @default.
- W4285198681 cites W2794833267 @default.
- W4285198681 cites W2801343489 @default.
- W4285198681 cites W2802650264 @default.
- W4285198681 cites W2808816873 @default.
- W4285198681 cites W2898583049 @default.
- W4285198681 cites W2900413769 @default.
- W4285198681 cites W2908439034 @default.
- W4285198681 cites W2914770371 @default.
- W4285198681 cites W2921081685 @default.
- W4285198681 cites W2974260792 @default.
- W4285198681 cites W2982161982 @default.
- W4285198681 cites W2983713274 @default.
- W4285198681 cites W2986558453 @default.
- W4285198681 cites W2990321183 @default.
- W4285198681 cites W2992890959 @default.
- W4285198681 cites W2999431040 @default.
- W4285198681 cites W3007286642 @default.
- W4285198681 cites W3009864904 @default.
- W4285198681 cites W3034300182 @default.
- W4285198681 cites W3043857828 @default.
- W4285198681 cites W3044871294 @default.
- W4285198681 cites W3046932676 @default.
- W4285198681 cites W3080857839 @default.
- W4285198681 cites W3092605621 @default.
- W4285198681 cites W3092676013 @default.
- W4285198681 cites W3093231756 @default.
- W4285198681 cites W3131380788 @default.
- W4285198681 cites W3139496483 @default.
- W4285198681 cites W3157778986 @default.
- W4285198681 cites W3167674076 @default.
- W4285198681 cites W3170013427 @default.
- W4285198681 cites W3174490474 @default.
- W4285198681 cites W3214977620 @default.
- W4285198681 cites W3217155948 @default.
- W4285198681 cites W4229442838 @default.
- W4285198681 cites W3147589090 @default.
- W4285198681 cites W3204940659 @default.
- W4285198681 doi "https://doi.org/10.7150/thno.75121" @default.
- W4285198681 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35836807" @default.
- W4285198681 hasPublicationYear "2022" @default.
- W4285198681 type Work @default.
- W4285198681 citedByCount "27" @default.
- W4285198681 countsByYear W42851986812022 @default.
- W4285198681 countsByYear W42851986812023 @default.
- W4285198681 crossrefType "journal-article" @default.
- W4285198681 hasAuthorship W4285198681A5000521986 @default.
- W4285198681 hasAuthorship W4285198681A5008721029 @default.
- W4285198681 hasAuthorship W4285198681A5018072765 @default.
- W4285198681 hasAuthorship W4285198681A5022684433 @default.
- W4285198681 hasAuthorship W4285198681A5026641678 @default.
- W4285198681 hasAuthorship W4285198681A5041492302 @default.
- W4285198681 hasAuthorship W4285198681A5047312522 @default.
- W4285198681 hasAuthorship W4285198681A5058382693 @default.
- W4285198681 hasBestOaLocation W42851986811 @default.